---
title: "CITIC Securities: Maintain \"Buy\" rating on BTBP, new production capacity is expected to improve production efficiency"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/249528684.md"
description: "CITIC Securities maintains a \"Buy\" rating on BTBP, believing that the new production capacity will enhance production efficiency, and the approval of new products will improve the comprehensive utilization rate of plasma. BTBP's plasma collection volume is rapidly increasing, with an expected collection volume of 2,781 tons in 2024. The company relies on China National Pharmaceutical Group and local cooperation to actively seek government support, and is expected to acquire more plasma stations in the future. By sharing technology and centralized research and development, the time for new product development will be shortened"
datetime: "2025-07-22T07:57:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/249528684.md)
  - [en](https://longbridge.com/en/news/249528684.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/249528684.md)
generator: "portal-rs"
---

# CITIC Securities: Maintain "Buy" rating on BTBP, new production capacity is expected to improve production efficiency

CITIC Securities research report points out that BTBP's plasma collection volume is rapidly increasing, and the new production capacity is expected to improve production efficiency. The approval of new products is expected to enhance the comprehensive utilization rate of plasma, maintaining an "overweight" rating. The company and its subsidiaries rely on the strategic cooperation background with China National Pharmaceutical Group and various local governments to actively seek support from government and health administrative departments at all levels. As of now, the company has 7 licenses with a total of 85 operating plasma stations and 22 plasma stations under construction, with a projected plasma collection volume of 2,781 tons in 2024. It is believed that the company currently holds 7 licenses distributed across multiple regions nationwide, and there will still be opportunities to acquire more plasma stations during the upcoming 14th Five-Year Plan period. The company rationally arranges the research varieties of its subsidiaries through internal technology sharing, adopting a centralized research and decentralized registration model to shorten research and development time and accelerate the advancement of new product development

### Related Stocks

- [600161.CN](https://longbridge.com/en/quote/600161.CN.md)

## Related News & Research

- [CMOC Group Declares Interim Dividend and Details Tax Arrangements for H Shareholders](https://longbridge.com/en/news/296383667.md)
- [New Buy Rating for CMOC Group (CMCLF), the Basic Materials Giant](https://longbridge.com/en/news/296660593.md)
- [Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate](https://longbridge.com/en/news/296689195.md)
- [China's AMEC to Invest USD520 Million to Boost Chip Equipment Capacity at Lingang Plant](https://longbridge.com/en/news/296452430.md)
- [giga! Equips All Eligible MILK Fund Scholars with One-year gigaFLEX+ Plan](https://longbridge.com/en/news/296587727.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**